AssayIndex

HYB-2604-D3661

Retatrutide · 20 mg declared · Shenzhen Hybio Pharmaceutical Co., Ltd. · manufactured 15 Apr 2026

CHARACTERISED
Lot code
HYB-2604-D3661
Supplier
HYB — Shenzhen Hybio Pharmaceutical Co., Ltd.
Compound
Retatrutide
Compound class
Incretin analogues and co-agonists
Declared label claim
20mg
Manufacture date
15 Apr 2026
Index quarter
2026-Q2
Independent assays
15
Laboratories involved
VendorInvestigate, Janoshik, PeptideMeter, Medutest, Kestrel, Nordanalyt
Provenance mix
Buyer-sourced ×13 · Laboratory-retained ×2
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 15
Median purity 98.44% n=15
Spread (max − min) 1.63pp n=15
Standard deviation 0.364pp n=15
95.596.397.197.998.799.5100.3This lot (HYB-2604-D3661)This lot (HYB-2604-D3661): Q1 98.31, median 98.44, Q3 98.64, n=15outlier 97.67outlier 99.30n=15All RetatrutideAll Retatrutide: Q1 97.92, median 98.44, Q3 98.82, n=510outlier 95.85outlier 95.94outlier 96.15outlier 96.38n=510 Purity (% area)
Figure 1. This lot's independent purity results against the whole Retatrutide record set in the index. The vertical line is the index acceptance specification for the incretin analogues and co-agonists class, 96.5 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 15

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041916HYB-2604-D3661VendorInvestigate2026-Q297.673.63Buyer-sourced0PASS
AX-2026-041917HYB-2604-D3661VendorInvestigate2026-Q298.193.34Buyer-sourced1MARGINAL
AX-2026-041918HYB-2604-D3661Janoshik2026-Q298.613.87Laboratory-retained0PASS
AX-2026-041919HYB-2604-D3661Janoshik2026-Q298.503.2393.1Laboratory-retained0PASS
AX-2026-041920HYB-2604-D3661PeptideMeter2026-Q298.653.90103.8Buyer-sourced0PASS
AX-2026-041921HYB-2604-D3661Medutest2026-Q298.244.42Buyer-sourced1FAIL
AX-2026-041922HYB-2604-D3661Kestrel2026-Q299.303.77Buyer-sourced0PASS
AX-2026-041923HYB-2604-D3661PeptideMeter2026-Q298.423.6295.4Buyer-sourced0PASS
AX-2026-041924HYB-2604-D3661Medutest2026-Q298.824.14Buyer-sourced0PASS
AX-2026-041925HYB-2604-D3661Janoshik2026-Q298.404.3888.6Buyer-sourced1MARGINAL
AX-2026-041926HYB-2604-D3661Nordanalyt2026-Q298.443.8297.4Buyer-sourced0PASS
AX-2026-041927HYB-2604-D3661VendorInvestigate2026-Q298.094.27106.0Buyer-sourced0PASS
AX-2026-041928HYB-2604-D3661PeptideMeter2026-Q298.393.71Buyer-sourced0PASS
AX-2026-041929HYB-2604-D3661VendorInvestigate2026-Q298.633.8792.5Buyer-sourced0PASS
AX-2026-041930HYB-2604-D3661Janoshik2026-Q298.663.09Buyer-sourced0PASS
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
VendorInvestigate497.67, 98.19, 98.09, 98.6398.1432min-0.1198.25
Janoshik498.61, 98.50, 98.40, 98.6698.5630min+0.0098.56
PeptideMeter398.65, 98.42, 98.3998.4228min-0.0598.47
Medutest298.24, 98.8298.5325min+0.0898.45
Kestrel199.3099.3015min+0.2499.06
Nordanalyt198.4498.4435min+0.0298.42

This lot contributes 15 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)98.0597.67divergence -0.39 pp vs batch median
Total impurities (% area)not stated2.33
Largest single impurity (% area)not stated1.01
Water (%)2.83.63
Counter-ion (%)9.39.60
Peptide content (%w/w)87.3not determined
Endotoxin (EU/mg)0.270.68
Method stated on certificateNOno method section — the result cannot be reconciled against any other
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
oxidised Trp (+16 Da)15 / 150.100.02–0.92
[D-Aib2]-diastereomer15 / 150.170.08–1.17
C18 diacid regioisomer15 / 150.060.02–0.08
aspartimide (−18 Da)13 / 150.100.02–0.14
truncated (5-39)8 / 150.640.49–1.01
des-Aib20 analogue8 / 150.080.01–0.13
incomplete Fmoc removal (+222 Da)7 / 150.390.34–0.47
retatrutide dimer7 / 150.020.02–0.02
Section 7

What this rollup does not establish